No Detail Found!

Pharmacogenetics of sulfonylurea: Presence of CYP2C9*2, CYP2C9*3 and a novel allele, CYP2C9*61, in Type 2 diabetes patients under sulfonylurea therapy

Author(s)
Sumaira Deen Muhammad Bioinformatics and Molecular Medicine Research Group, Dow Research Institute of Biotechnology and Biomedical Sciences, Dow College of Biotechnology, Dow University of Health Sciences, Karachi, Pakistan;Bolan University of Medical and Health Sciences, Quetta, Pakistan
Hazar Khan Bioinformatics and Molecular Medicine Research Group, Dow Research Institute of Biotechnology and Biomedical Sciences, Dow College of Biotechnology, Dow University of Health Sciences, Karachi, Pakistan;Bolan University of Medical and Health Sciences, Quetta, Pakistan
Mushtaq Hussain Bioinformatics and Molecular Medicine Research Group, Dow Research Institute of Biotechnology and Biomedical Sciences, Dow College of Biotechnology, Dow University of Health Sciences, Karachi, Pakistan
Tehseen Fatima Zeb Bioinformatics and Molecular Medicine Research Group, Dow Research Institute of Biotechnology and Biomedical Sciences, Dow College of Biotechnology, Dow University of Health Sciences, Karachi, Pakistan
Darshan Kumar National Institute of Diabetes and Endocrinology, Dow University of Health Sciences,Karachi,Pakistan
Rahimullah Rahi Bolan University of Medical and Health Sciences,Quetta,Pakistan
Mahayrookh Asif Bioinformatics and Molecular Medicine Research Group, Dow Research Institute of Biotechnology and Biomedical Sciences, Dow College of Biotechnology, Dow University of Health Sciences, Karachi, Pakistan
Akhter Ali Balooch National Institute of Diabetes and Endocrinology, Dow University of Health Sciences,Karachi,Pakistan
Abstract
CYP2C9 is an important member of the cytochrome P450 gene family involved in the metabolism of 15% of the drugs including an oral antidiabetic agent sulfonylurea. This study aims to investigate the frequency of CYP2C9*2 and CYP2C9*3 alleles of the gene in the sulfonylurea treated diabetic subjects in Pakistan. Briefly, total 105 patients were included in the study and segregated as control (24) and test (81) based on the clinical manifestations after taking sulfonylurea. Genomic DNA was extracted from blood of the subjects and amplified using CYP2C9 specific primers for exon 3 and exon 7 and then subjected to DNA sequencing. Alignment of the sequences with the reference sequence shows presence of CYP2C9*3/*3, CYP2C9*1/*3 and CYP2C9*1/*2 genotypes in the test cases but only the latter two were found in the control cases. In addition a novel allele, CYP2C9*61 in the heterozygous state, was also identified frequently in the test cases. Molecular structure comparison also showed variations in the structural features of protein encoded by the allelic variants. To the best of our knowledge, the present data is the first report for CYP2C9 allelic variations in the indigenous diabetic subjects and also report the existence of novel allelic variant of CYP2C9, CYP2C9*61.
Publication Details
Page(s) 1771-1777
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 33, Issue: SUP4, Year: 2020

Request the full text from PASTIC

Keywords
Diabetes Mellitus, Sulfonylurea, Pharmacogenetics, Diabetes mellitus, CYP2C9, Diabetes mellitus
References
Adithan C,Gerard N,Vasu S,Balakrishnan R,Shashindran CH,Krishnamoorthy R .2003 .Allele and genotype frequency of CYP2C9 in Tamilnadu population. Eur. J. Clin. Pharmacol, 59(8-9) : 707-709.
Adnan M and Aasim M .2020 .Prevalence of Type 2 Diabetes Mellitus in Adult Population of Pakistan: A Meta-Analysis of Prospective Cross-Sectional Surveys. , 86 : 1.
Bhatt D,Chauhan N,Sharma A,Dhawan D,Bhatt RV,Phatak S,Padh H S .2014 .Investigating the role of plasma glucose concentration as a phenotypic marker for CYP2C9 genetic variants, in the diabetic population of Gujarat. Indian J. Pharma. Sci., 76 : 72.
Billingham SA,Whitehead AL,Julious SA .2013 .An audit of sample sizes for pilot and feasibility trials being undertaken in the United Kingdom registered in the United Kingdom Clinical Research Network database. BMC Med, 13 : 104.
Broichhagen J,Schönberger M,Cork SC,Frank JA,Marchetti P,Bugliani M,Shapiro AJ,Trapp S,Rutter GA,Hodson DJ,Trauner D .2014 .Optical control of insulin release using a photoswitchable sulfonylurea. Nat. Commun, 5 : 1-1.
Cavallari LH,Momary KM .2019 .Pharmacogenetics in Cardiovascular Diseases. , : 133-179.
Cordiner RL,Pearson ER .2019 .Reflections on the sulphonylurea story: A drug class at risk of extinction or a drug class worth reviving? Diabetes Obes. , 21(4) : 761-771.
Hashemi-Soteh SM,Shahabi-Majd N,Gholizadeh AR,Shiran MR .2012 .Allele and genotype frequencies of CYP2C9 within an Iranian population (Mazandaran). Genet.Test Mol. Bioma, 16(7) : 817-821.
Holstein A,Hahn M,Patzer O,Seeringer A,Kovacs P,Stingl J .2011 .Impact of clinical factors and CYP2C9 variants for the risk of severe sulfonylureainduced hypoglycemia. Eur. J. Clin. Pharmacol, 67(5) : 471-476.
Hosseinkhani Z,Sadeghalvad M,Norooznezhad F,Khodarahmi R,Fazilati M,Mahnam A,Fattahi A,Mansouri K A,> G .2018 .A polymorphism in patients under warfarin therapy in city of Kermanshah. Res. Pharm. Sci., 13(4) : 377.
Loganadan NK,Huri HZ,Vethakkan SR,Hussein Z SR .2016 .Genetic markers predicting sulphonylurea treatment outcomes in type 2 diabetes patients: current evidence and challenges for clinical implementation. , 16(3) : 209-219.
Lv W,Wang X,Xu Q,Lu W .2020 .Mechanisms and characteristics of sulfonylureas and glinides. Curr. Top. Med, 20 : 37-56.
Qayyum A,Najmi MH,Mansoor Q,Farooqi ZU,Naveed AK,Hanif A,Kazmi SA,Ismail M .2017 .Frequency of common CYP2C9 polymorphisms and their impact on warfarin dose requirement in Pakistani population. Clin Appl, 23(7) : 800-6.
Qayyum A,Najmi MH,Raza SI,Rajput TA,Naveed AK .2019 .Relationship of S/R warfarin ratio with CYP2C9 genotypes in Pakistani population. Pak. J. Pharm. Sci., 32(4) : 1581-1588.
Qian D,Zhang T,Tan X,Zheng P,Liang Z,Xie J,Jiang J,Situ B .2018 .Comparison of antidiabetic drugs added to sulfonylurea monotherapy in patients with type 2 diabetes mellitus: A network meta-analysis. PLoS One, 13(8) : e0202563.
Rados DV,Pinto LC,Remonti LR,Leitao CB,Gross JL CB .2016 .The association between sulfonylurea use and all-cause and cardiovascular mortality: a metaanalysis with trial sequential analysis of randomized clinical trials. PLoS Med, 13(4) : e1001992.
Ragia G,Petridis I,Tavridou A,Christakidis D,Manolopoulos VG D .2009 .Presence of CYP2C9* 3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas. Pharmacogenomics, 10(11) : 1781-1787.
Saberi M,Ramazani Z,Rashidi H,Saberi A .2020 .The Effect of CYP2C9 genotype variants in Type 2 diabetes on the pharmacological effectiveness of sulfonylureas, diabetic retinopathy, and nephropathy. Vasc. Health Risk Manag., 16 : 241.
Salam RF,Zeyada R,Osman NA .2014 .Effect of CYP2C9 gene polymorphisms on response to treatment with sulfonylureas in a cohort of Egyptian type 2 diabetes mellitus patients. Comp. Clin. Path, 23 : 341-346.
Siddiqi AI,Khan DA,Khan FA,Naveed AK .2010 .Impact of CYP2C9 genetic polymorphism on warfarin dose requirements in Pakistani population. Pak. J. Pharm. Sci., 23(2) : 417-422.
Sola D,Rossi L,Schianca GP,Maffioli P,Bigliocca M,Mella R,Corlianò F,Fra GP,Bartoli E,Derosa G .2015 .Sulfonylureas and their use in clinical practice. Arch. Med, 11(4) : 840.
Thompson JD,Higgins DG,Gibson TJ .1994 .CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res, 22(22) : 4673-4680.
Volkamer A,Kuhn D,Rippmann F,Rarey M .2012 .DoGSiteScorer: a web server for automatic binding site prediction, analysis and druggability assessment. , 28(15) : 2074-2075.
Waterhouse A,Bertoni M,Bienert S,Studer G,Tauriello G,Gumienny R,Heer FT,de Beer TA,Rempfer C,Bordoli L,Lepore R .2018 .SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res, 46 : W296-303.
Wester MR,Yano JK,Schoch GA,Yang C,Griffin KJ,Stout CD,Johnson EF .2004 .The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-Å resolution. J. Biol. Chem, 279(34) : 35630-35637.
Yasmeen F,Ghafoor MB,Khalid AW,Latif W,Mohsin S,Khaliq S S,Throm S .2015 .Analysis of CYP2C9 polymorphisms (*2 and *3) in warfarin therapy patients in Pakistan. Association of CYP2C9 polymorphisms (*2 and *3) with warfarin dose, age, PT and INR. , 40(2) : 218-224.
0

Citations

0

Downloads

16

Views